Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease by Kim, Hye Yun et al.
Taurine in drinking water recovers
learning and memory in the adult APP/
PS1 mouse model of Alzheimer’s disease
Hye Yun Kim1,2,3*, Hyunjin V. Kim1,2*, Jin H. Yoon1,4*, Bo Ram Kang1,2, Soo Min Cho1,2, Sejin Lee1,2,
Ji Yoon Kim1,2, Joo Won Kim1,5, Yakdol Cho6, Jiwan Woo6 & YoungSoo Kim1,2
1Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea, 2Biological
Chemistry Program, Korea University of Science and Technology, Daejeon, Republic of Korea, 3Department of Biochemistry and
Biomedical Sciences, Seoul National University, College of Medicine, Seoul, Republic of Korea, 4Department of Biology,
Massachusetts Institute of Technology, Cambridge, MA, U.S.A., 5Department of Applied Chemistry, Dongduk Women’s University,
Seoul, Republic of Korea, 6Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul,
Republic of Korea.
Alzheimer’s disease (AD) is a lethal progressive neurological disorder affecting the memory. Recently, US
Food and Drug Administration mitigated the standard for drug approval, allowing symptomatic drugs that
only improve cognitive deficits to be allowed to accelerate on to clinical trials. Our study focuses on taurine,
an endogenous amino acid found in high concentrations in humans. It has demonstrated neuroprotective
properties against many forms of dementia. In this study, we assessed cognitively enhancing property of
taurine in transgenic mouse model of AD.We orally administered taurine via drinking water to adult APP/
PS1 transgenic mouse model for 6 weeks. Taurine treatment rescued cognitive deficits in APP/PS1 mice up
to the age-matchingwild-typemice inY-maze and passive avoidance tests withoutmodifying the behaviours
of cognitively normal mice. In the cortex of APP/PS1 mice, taurine slightly decreased insoluble fraction of
Ab. While the exact mechanism of taurine in AD has not yet been ascertained, our results suggest that
taurine can aid cognitive impairment and may inhibit Ab-related damages.
R
ecovery from dementia is the key clinical benefit to the patients of Alzheimer’s disease (AD). This has
become evident after consecutive failures in clinical trials for disease-modifying drugs that target neuro-
pathological hallmarks. Accordingly, the US Food and Drug Administration loosened the standard for AD
drug approval1. Their new guidance suggests accelerated regulatory pathways for drugs that improve cognitive
deficits alone in early stages of AD. Albeit flexible in mechanisms of action, these symptomatic drugs must be
assessed in early-stage AD patients with overt dementia and apparent biomarkers, such as amyloid plaques and
tau tangles. The next generation acetylcholinesterase inhibitors may well fit into the accelerated pathways.
However, the unnecessary stimulation of the normal cholinergic systems in the brains of AD patients and, even,
non-demented subjects remains to be solved2.
Taurine, 2-aminoethanesulfonic acid, is the second most abundant endogenous amino acid in the central
nervous system (CNS) and plays multiple roles in our body: thermoregulation, stabilization of protein folding,
anti-inflammatory effects, antioxidation, osmoregulation, calcium homeostasis and CNS development3–9
(Figure 1). Due to its nontoxic and curative properties, taurine is frequently found in food, drinks and drugs
for treating liver and heart disorders10–13. Recently, taurine has shown therapeutic effects as a cognitive enhancer
in animal models of non-AD neurological disorders. Taurine recovers memory impairments of mice induced by
alcohol, pentobarbital, sodium nitrite and cycloheximide without any observable effects on other behaviours
includingmotor coordination, exploratory activity and locomotor activity14. Cognitive deficits of rats from excess
manganese exposure are improved, and upregulated acetylcholinesterase activity is partially restored after taurine
administration15. The intracerebroventricular administration of taurine protects mice from hypoxia-induced
learning impairment16. In addition, intravenously administered taurine significantly improves post-injury func-
tional impairments of traumatic brain injury in rats17. Taurine supplementation has also been found to rescue
ageing-dependent loss of visual discrimination in mice18. In streptozotocin-induced sporadic dementia rat
models, cognitive impairment and abnormal acetylcholinesterase activity is ameliorated by taurine19. Notably,
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Taurine also has multiple disease-modifying roles to prevent or
cease neuropathology of AD. During the development of AD, amy-
loid-b (Ab) progressively misfolds into toxic aggregates, which are
strongly associated with neuronal loss, synaptic damages and brain
atrophy. The electronmicroscopy study indicates that taurine weakly
inhibits Ab aggregation21. Anti-inflammatory and anti-oxidant
properties of taurine also protect neuronal cells and mitochondria
from neurotoxicity of Ab. By activating GABA and glycine receptors,
taurine inhibits excitotoxicity caused by Ab-induced glutamatergic
transmission activation22. Taurine is also observed to attenuate Ab-
associated neuronal cell death, mitochondrial permeability trans-
ition pore opening, mitochondrial dysfunction and intracellular
reactive oxygen species generation by activating Sirtuin 123–26.
Therapeutic effects of taurine remain to be investigated in demented
animal models with AD pathology. Considering the reevaluation of
anti-amyloidogenic homotaurine for the potential role to ameliorate
the cholinergic transmission in early AD, its analog compounds such
as taurine are valuable therapeutic candidates for both cognitive
enhancement and disease-modification (Figure 1)27.
In this study, we examined both symptomatic and disease-
modifying effects of taurine in the demented adult APP/PS1 trans-
genic ADmouse model. Taurine was orally administered to the mice
via drinking water for 6 weeks. The Y-maze and the passive avoid-
ance tasks were then performed in succession to test for improve-
ment of the spatial working memory and the contextual learning
abilities, respectively. After sacrificing the animals for their cere-
brospinal fluid (CSF) and brains, we measured alterations of Ab
levels in soluble, insoluble and plaque forms by sandwich enzyme-
linked immunosorbent assays (ELISA) and Ab burden assay (ThS
staining). In addition, we measured the level of reactive astrocytes by
immunohistochemistry (IHC) and western blots.
Results
Animal model and oral administration of taurine. To examine
therapeutic efficacy of orally administered taurine as a cognitive
enhancer in the early dementing stage of AD, we utilized APPswe/
PS1-dE9 transgenic mouse model at the age of 7 months and dissolved
taurine in the drinking water for 6-week administration. This mouse
model produces elevated amount of human Ab peptides by expressing
mutant human amyloid precursor protein (APP) and presenilin
protein 1 (PS1)28. This model is reported to express abnormal
learning and memory behaviours with Ab/tau alterations as early as
the age of 6 months29,30. The 7-month old APP/PS1 mice (n 5 19,
male) and their age-matched wild-type littermates (n 5 20, male)
were divided into groups depending on presence of taurine in the
drinking water. To orally administer 1,000 mg/kg/day of taurine to
the mice, amounts of taurine in each water container was calculated
based on daily water consumption and weekly check-up on body
weights. Oral dosage of 1,000 mg/kg/day to mice was justified based
on previously reported taurine in vivo studies and the median lethal
dose (over 7,000 mg/kg)14–20. Throughout the experiment we did not
observe any changes in hair loss, water consumption or body weight.
Taurine improves spatial working memory in APP/PS1 mice in
the Y-maze task. To assess the spatial working memory of APP/PS1
mice, we performed the Y-maze test at the end of 6-week taurine
administration. In the 3-armed Y-shaped maze, a mouse is free to
explore, and the sequence of entries is recorded to determine the
number of visits to 3 different arms in a row. The analyzed percent
alternation reflects the function of visual cortex function
of the subjected mouse, and higher percent alternation indicates
better spatial memory. In this study, we found that taurine
supplementation significantly improved behavioural performance
of the APP/PS1 mice on the Y-maze test as compared to the water-
only APP/PS1 group (Figure 2A). The spatial working memory of
APP/PS1 mice was recovered up to wild-type levels (Figure 2A). We
found insignificant changes among the total number of arm
entries, dismissing hyperactivity as a possible argument for
cognitive improvement (Figure 2A).
Taurine improves hippocampal memory in APP/PS1 mice in the
passive avoidance task. To evaluate the hippocampal memory of
APP/PS1 mice, we performed the passive avoidance test 2 days after
the Y-maze test. The passive avoidance test is a fear-motivated test to
assess the function of hippocampus and amygdala of the subject. The
test requires rodents to resist their affinity for the darker chamber and
remain in the lighter chamber of a 2-chamber box. In the acquisition
phase, a mouse is placed inside the bright chamber and receives a
shock when it traverses to the dark side. After 24 hrs, the mouse is
Figure 1 | Structures of taurine and homotaurine.
Figure 2 | Improvement in spatial and hippocampal learning behaviours
in taurine-treated transgenic mice. 7-month old wild-type (Wt) and age-
matched APP/PS1 transgenic (Tg) male mice were orally administered
water or taurine (1,000 mg/kg/day) for 6 weeks (n 5 8–10 per group).
After 6 weeks, behavioural tests were administered to the 8.5-month old
mice. (A) Y-maze. Average alternation (%) of each group of mice was
calculated. (B) Passive avoidance. Average latency time in seconds for each
group of mice was measured. One-way ANOVA followed by Bonferroni’s
post-hoc comparisons tests were performed in all statistical analyses (*P,
0.05, **P , 0.01, ***P , 0.001, n.s.: no significance).
www.nature.com/scientificreports
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again placed in the bright chamber of the box, and how well it
remembers the shock is measured by the latency in avoiding the
dark chamber. Higher latency value translates to better retention of
memory from the foot-shock given during the learning phase.
Consistent with the results obtained from the Y-maze, taurine was
observed to significantly enhance behavioural performance of the
APP/PS1 mice in the pass avoidance tasks as compared to the non-
treated APP/PS1 group (Figure 2B). The hippocampal memory of the
taurine-treated APP/PS1 mice was recovered to the level similar to
that of wild-type mice (Figure 2B). Similar to the results from the Y-
maze test, behavioural alterations of the wild-type by taurine
treatment was insignificant (Figure 2B).
Taurine decreases insoluble Ab42 in the cortex of APP/PS1 mice.
Ab accumulation in the brain reflects the onset of AD31. As taurine
was reported to bind Ab peptides with weak anti-fibrillogenic effect,
we measured alterations of plaque, soluble and insoluble forms of
Ab21,32. To examine the effect of orally administered taurine on the
alteration of plaque burden, brains of APP/PS1 mice were sectioned
after behavioural tests, and then stained with thioflavin S (ThS). ThS
was used to visualize b-sheet-rich Ab plaques. In comparison to the
non-treated APP/PS1 group, no significant difference was found in
numbers, area or average size of plaques in taurine-treated APP/PS1
group (Figure 3). Consistent with the results from ThS staining, we
did not observe alterations in levels of plaques and amyloid precursor
protein by IHC using the monoclonal anti-Ab antibody, 6E10
(Figure 4A and 4B). Among various isomers of Ab, Ab42 is the
most amyloidogenic and neurotoxic. In order to determine
whether Ab42 peptides were involved in amelioration of cognitive
deficits in APP/PS1 mice, we prepared brain lysates of animals
subjected to aforementioned behavioural studies and isolated
soluble and insoluble Ab fractions of both the hippocampus and
the cortex for sandwich-ELISA. In the hippocampal region, levels
of soluble and insoluble Ab42 were not altered by taurine
administration (Figure 4C). In addition, we did not observe
changes in soluble Ab42 levels in the cortices of APP/PS1 mice by
taurine treatment. On the contrary, we found a significant decrease
in the level of Ab42 in the cortical insoluble fraction of the taurine-
treated APP/PS1 mice as compared to the non-treated APP/PS1
group (Figure 4C). CSF Ab42 and tau levels are associated with
neuropathological changes in AD brains33. In comparison between
2 transgenic groups, we did not observe differences in CSF Ab42
(Figure 4D) or tau levels (data not shown). Collectively, these
results indicate that 6-week oral administration of taurine
(1,000 mg/kg/day) only reduced levels of Ab42 insoluble fractions
of the cortex.
Taurine treatment increases levels of reactive astrocytes in the
hippocampus and the cortex. Reactive astrocytes are found in
various CNS disease brains to limit inflammation and to protect
Figure 3 | Ab burden tests in the hippocampi andwhole brains inmice. 7-month oldwild-type (Wt) or age-matchedAPP/PS1 transgenic (Tg)malemice
were orally administrated water or taurine (1,000 mg/kg/day) for 6 weeks (n5 8–10 per group). (A) ThS-stained Ab burden in whole brains (scale bar,
1 mm) and hippocampal regions (scale bar, 200 mm)of each group. (B) normalized (%) number, area or average size of Ab burden to 8.5-month oldmice
level in whole brains. The mouse brain schematic diagram was adapted from the Mouse Brain Atlas48 (green box: regions of brain images). One-way
ANOVA followed by Bonferroni’s post-hoc comparisons tests were performed in all statistical analyses (*P, 0.05, **P, 0.01, ***P, 0.001, n.s.: no
significance).
www.nature.com/scientificreports
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neurons from tissue degeneration34. In AD, reactive astrocytes
cluster around Ab plaques as a glial response to the neural injury
associated with Ab35. Therefore, we measured glial fibrillary acidic
protein (GFAP), a marker for astrocytosis, in the brains of taurine-
treated mice by IHC and western blots. In IHC analyses, reactive
astrocytes were colocalized with both ThS- and 6E10-stained plaques
in transgenic mouse brains (Figure 4A and 4B). To quantify levels of
GFAP expression, we performed western blot analyses. Interestingly,
we found that oral administration of taurine induced increase of
reactive astrocytes in both the wild-type and transgenic mice
(Figure 4E). Because taurine treatment selectively enhanced
behavioural performance of APP/PS1 groups in Y-maze and
passive avoidance tasks without affecting wild-type mice, it is
difficult to correlate the increase of astrocytosis with learning and
memory in this study.
Discussion
Here we report that taurine in drinking water rescues Alzheimer-like
learning and memory deficits of adult APP/PS1 double transgenic
mice without modifying the behaviours of cognitively normal mice.
Our current study complements a previous study that reported the
ability of taurine to improve learning and retention in aged FVB/NJ
mouse model compared to their untreated controls36. Unlike APP/
PS1mouse model, which expresses human Ab and amyloidogenesis,
FVB/NJ mouse model induces retinal degeneration. The cognitive
impairment induced in their study was through ageing alone and the
Figure 4 | Biochemical analyses of GFAP andAb in the hippocampi and the cortices. 7-month old wild-type (Wt) and age-matched APP/PS1 transgenic
(Tg) male mice were orally administered water or taurine (1,000 mg/kg/day) for 6 weeks (n 5 8–10 per group). Immunohistochemical analyses
of (A) hippocampal regions and (B) cortical regions of 8.5-month old mice were perfused and sectioned. Abs in the brain sections were stained by 6E10
antibody and ThS. Ab plaques with ThS staining (1st row): blue, All Abs including APP (2nd row): green, GFAP was stained by anti-GFAP
(3rd row): red, DAPI: blue (a location indicator). The bottom rows show merged images with DAPI staining. Scale bars, 50 or 200 mm, respectively. The
mouse brain schematic diagramwas adapted from theMouse Brain Atlas48 (green box: regions of brain images). (C)Quantifications of Ab in brain lysates
or (D) CSF Ab analyses by sandwich-ELISA. Ab-soluble (Sol.) fraction (sucrose-tris lysis buffer) and Ab-insoluble (Insol.) fraction (guanidine-HCl lysis
buffer) of brain lysates were analyzed. b-actin is a loading control. (E) Western blot analyses of brain lysates obtained from hippocampal and cortical
regions. One-way ANOVA followed by Bonferroni’s post-hoc comparisons tests were performed in all statistical analyses (*P, 0.05, **P, 0.01, ***P,
0.001, n.s.: no significance).
www.nature.com/scientificreports
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following consequences, while APP/PS1 mouse model acquired cog-
nitive deficits through increased production and aggregation of
human Ab peptides. In addition to ameliorating deficits associated
with ageing andAb, taurine proved to be effective with other forms of
dementia: hypoxia-induced learning impairment, ischemic stroke-
induced learning impairment, chemical-induced sporadic dementia
of Alzheimer’s type, and alcohol-induced brain impair-
ment14,16,19,37,38. Consistent with our findings, taurine has been
reported as ineffective to enhance spatial learning and memory in
cognitively normal mice20. Accordingly, unlike acetylcholinesterase
inhibitors, taurine seems to be dementia-specific, which may have
great clinical impacts as a selective cognitive enhancer.
The results from our study indicate that taurine may play a role in
preventing cognitive impairment in AD-like mouse model.
However, the exact mechanism is not clear how taurine induces
improvement of abnormal behaviours in AD model mice without
the significant inhibition of Ab amyloidogenesis. The sandwich-
ELISA results suggest that taurine weakly decreases Ab levels in
the insoluble fraction of brain lysates but rarely alters concentrations
of soluble Ab, including monomers and oligomers. In addition, his-
tochemical analyses reveal that taurine does not affect b-sheet-rich
plaques. As the current methods to isolate Ab in brain lysates into
soluble, insoluble and guanidine-soluble fractions do not clearly
define the contents, it is difficult to indicate specific alterations of
monomers, oligomers, protofibrils and plaques. However, it is con-
siderable that the levels of protofibrils with immature b-structures
may be decreased by taurine treatment. Existence of protofibrils
often provides confusing results in biochemical analyses measuring
levels of high molecular weight Ab aggregates39. It is also unclear
exactly how taurine interacts with Ab or by what mechanism it
decreases the Ab level. There have been proposals regarding calcium
and chloride modulation, but further studies are needed to reveal
how taurine decreases Ab concentration in the brain. One hypothesis
on how taurine can affect Ab levels is the direct interaction between
taurine and Ab peptides in the brain. Previous studies on influences
of taurine on amyloidogenesis have been controversial. Taurine in
1 mM slightly prevented Ab peptide comprising the residues 25–35
from polymerizing into fibrils21, suggesting a small inhibiting effect
of taurine on Ab peptide aggregation. However, in the presence of
20 mM of taurine at pH of 5.5, Ab40 peptides accelerated in aggrega-
tion but not at pH of 7.439. Another hypothesis is that the sulfonic
acid group in taurine may bind to Ab peptides and prevent glycosa-
minoglycans from binding to Ab, thereby inhibiting Ab aggrega-
tion32,40. The structural similarity of homotaurine (tramiprosate), a
former drug candidate, and taurine (Figure 4) suggests that taurine
may also interfere in glycosaminoglycans recruiting Ab41.
We observed the increased expression of GFAP by taurine, in
both wild-type and transgenic mice. Because many investigations
reported reduced reactive astrocytes by taurine treatment, additional
studies are warranted to determine correlation of taurine supple-
mentation and GFAP alterations. Although such explorations may
be beyond the scope of the current study, it is noteworthy that long-
term administration of high-dose taurine (200 mg/kg/day, intraper-
itoneal) was also found to induce over expression of GFAP during
improvement of the spatial learning and memory ability in Sprague-
Dawley rats15.
Our results suggest that taurine has a potential in treating dele-
terious effects on cognitive functions of AD. Taurine is already in
clinical uses for congestive heart failure and liver disease with no
known side-effects. Current prescription limits taurine supple-
mentation to one year, but there is a dearth of adverse evidence for
long-term taurine use. Previous studies assert that there are signs of
beneficial effects in athletes42 and in sleep-deprived students43.
Moreover, the fact that taurine is effective via drinking water is a
great convenience for the AD patients. Additional studies are war-
ranted to determine whether these favorable actions of taurine will
translate into a therapy that might potentially be useful in the early
stage of AD.
Methods
Materials. DMSO, sodium carboxymethyl cellulose, taurine (median lethal dose:
greater than 7,000 mg/kg), thioflavin S, glycine and sucrose were purchased from
Sigma-Aldrich (St. Louis, Missouri, USA). PBS was obtained from Gibco (Grand
Island, New York, USA). 96-well plates (clear, black) were purchased from Corning
(New York, New York, USA). Deionized water was generated by Milli-Q plus water
system from Milliopore (Bedford, Massachusetts, USA).
Animals. Double APP/PS1 transgenic mice (strain name: B6C3-Tg (APPswe,
PSEN1De9) 85Dbo/J) and wild type (B6C3F1) mice were obtained from Jackson
Laboratory (Bar Harbor, Maine, USA). Both genes APP and PSEN1 were confirmed
before the experiment began via a PCR instrument from Bio-Rad (S1000 Thermal-
Cycler) using the standard PCR condition from Jackson Laboratory, the PCR-remix
provided by Cosmo-Genetech (G-taq PCR premix kit, CMT-6002), and DNA from
mice tails. Themice were 7months of age at the beginning of the experiment, and they
were housed in a room under controlled temperature, with an alternating 12 hrs light-
dark cycle and access to food and water ad libitum. The behavioural tests were
performed during the light period in a sound-attenuated and air-regulated
experiment room. There was at least 30 min of habituation time before the
behavioural tests began. All animal experiments were carried out in accordance with
the National Institutes of Health guide for the care and use of laboratory animals
(NIH Publications No. 8023, revised 1978). The animal studies were approved by the
Institutional Animal Care and Use Committee of Korea Institute of Science and
Technology.
Repeated oral dose studies.Taurine was orally administered via water at dose level of
0 (control) or 1,000 mg/kg/day for 6 weeks to 7-month old male APP/PS1 and wild-
type mice: taurine-treated APP/PS1 (n5 11), non-treated APP/PS1 (n5 8), taurine-
treated wild-type (n 5 10) and non-treated wild-type (n 5 10). We speculated that
administering taurine orally via water should be effective since taurine can cross the
blood-brain barrier, albeit in small amounts44. Amount of water intake permouse was
calculated by measuring the water consumption every day for each cage. Body weight
of each animal was measured on the 0th day and every 7 days afterwards. After the
behavioural tests, the brains and CSF were collected under ether anesthesia. 19 Mice
were perfused, and the other 20 mice had their cortices and hippocampi extracted.
Y-maze. The Y-maze test was performed after 6 weeks of oral taurine administration.
The apparatus was a black, plastic maze with 3 arms (40 L 3 10 W 3 12 H cm)
labeled A, B and C that converged to the middle, forming an equilateral triangle with
4 cm at its longest axis. Mice were placed at the end of one arm and allowed to move
freely through themaze for 8 min, and the sequence of armmovements wasmanually
recorded. When all 4 limbs of the mouse were within the pathway, it was considered
an entry. An alternation was counted when a mouse successively entered 3 different
arms. Spontaneous alternation behaviour was calculated based on the following
equation:




Passive avoidance.The passive avoidance test was performed 2 days after the Y-maze
test. A 2-compartment shuttle chamber with a light compartment and a darker one
containing a shock generator was used. For the acquisition trial, each mouse was first
placed in a light chamber. After 10 sec, the door between the light/dark compartments
was opened so that the mouse could move freely into the dark chamber. Upon
entering the dark chamber, the door closed immediately and an electric foot shock
(0.5 mA, 1 sec, once) was delivered through the floor grid. The mouse was then
returned to its original cage for 24 hrs. For the retention trial after the 24 hrs, each
mouse was placed into the light chamber, and the latency time between placement
and entry into the dark chamber was measured (maximum 300 sec). Data was
recorded and analyzed using a video camera-based Ethovision System (Nodulus,
Netherlands).
Data analyses including recordings of all behavioural responses were transcribed
manually into the computer-acceptable format by keeping research colleagues blind.
Brain and CSF sample preparation. After the behavioural tests, mice were
anesthetized with 2% avertin (20 mg/g, i.p.). Each group was divided approximately
into half for perfusion and the other half for brain lysate. Brain lysates were developed
by dissecting the hippocampal and cortical regions ofmouse brains and homogenized
using a lysis buffer (10 mM Tris-HCl, 5 mM EDTA in 320 mM sucrose, pH 7.4)
containing 13 proteinase inhibitors cocktail for 30 min on ice45. The homogenates
were centrifuged at 13,500 rpm, 4 uC for 30 min. Concentrations of cortical and
hippocampal lysate supernatants were determined by Bradford protein assay. The
perfusion beganwith 0.9% saline followed by ice cold 4%paraformaldehyde (pH 7.4).
Excised brains were post-fixed overnight in 4% paraformaldehyde and immersed in
30% sucrose for 48 hrs for cryoprotection. The perfused brain samples were cut at
35 mm using a Cryostat (Microm HM 525, Thermo Scientific, Waltham, MA, USA)
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7467 | DOI: 10.1038/srep07467 5
andmounted onto glass slides. CSF sampling was performed according to themethod
described previously46. Anesthetized mice were placed prone, and their cisterna
magna were surgically exposed. The exposed meninges were penetrated with
laboratory-produced capillary tube that had a tapered tip to obtain CSF. About 3–
5 mL of CSF samples were obtained from each mouse.
Western blot. 20 mg of brain lysates were analyzed using a 10% SDS-gel
electrophoresis. The proteins on the gel were transferred to a PVDFmembrane. After
the transfer, the membrane was blocked, then antibodies were employed.
Immunoreactive bands were visualized using an enhanced chemiluminescence
technique (Bio-Rad). The primary antibody information is the following: glial
fibrillary acidic protein (GFAP, Millipore AB5541, 151,000) and actin as the loading
control (MilliporeMAB1501R, 1510,000). The secondary antibody information is the
following: anti-mouse (Santa-Cruz, 1520,000) and anti-rabbit (Santa Cruz, 153,000).
ThS staining and immunohistochemistry. Ab plaque burden in cryo-sectioned
brains were visualized using ThS staining. ThS was dissolved in 50% of ethanol at
500 mM and brain sections were stained for 7 min. Then, to remove non-specific
binding of ThS dye, the sections were rinsed through 100, 95 and 90% of ethanol for
10 sec each and moved into PBS in succession. The brain sections were also stained
for Ab and GFAP (Millipore AB5541). Ab was stained by monoclonal antibody
(6E10). DAPI was also used for indication of the brain region. The images were taken
on a Carl Zeiss LSM700 confocal microscope and a Leica DM2500 fluorescence
microscope47. Data analyses including recordings of all behavioural responses were
transcribed manually into the computer-acceptable format by keeping research
colleagues blind. The mouse brain schematic diagrams in data were adapted from the
Mouse Brain Atlas48.
Sandwich-ELISA. Sandwich-ELISA kit was purchased from Invitrogen, and the
assays were performed on brain lysates and CSF following the manufacturer’s
directions and using the antibodies provided in the kit.
Statistics. Graphs were obtained with GraphPad Prism 5, and the statistical analyses
were performed with one-way ANOVA followed by Bonferroni’s post-hoc
comparisons (*P, 0.05, **P, 0.01, ***P, 0.001, n.s.: no significance). The error
bars represent the SEMs.
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